Fiona Barry

@FionaReporter

Intrepid pharmaceutical reporter for . Fiona.Barry@globaldata.com / . Previously with

Vrijeme pridruživanja: ožujak 2014.

Tweetovi

Blokirali ste korisnika/cu @FionaReporter

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @FionaReporter

  1. proslijedio/la je Tweet

    Our latest collaboration with reveals the month's opportunities and threats to in the form of approvals and discontinuations

    Poništi
  2. proslijedio/la je Tweet
    30. sij

    Who in your organization is tracking the coronavirus? Its spread is impacting every industry and function. Plc has launched the Coronavirus Influencers dashboard on our Intelligence Centers to educate on: -- what the world's leading coronaviru…

    Poništi
  3. proslijedio/la je Tweet
    31. sij
    Poništi
  4. proslijedio/la je Tweet
    31. sij
    Poništi
  5. 31. sij

    This month's BPOR includes the launch of $1.1billion The Center for Breakthrough Medicines for

    Poništi
  6. proslijedio/la je Tweet
    23. sij
    Poništi
  7. proslijedio/la je Tweet
    6. sij
    Poništi
  8. proslijedio/la je Tweet
    20. pro 2019.

    Check out the latest Emerging Markets Outsourcing Report from PharmSource Intelligence, part of the GlobalData Pharma Intelligence Center.

    Poništi
  9. proslijedio/la je Tweet
    5. stu 2019.

    The future is bright for marketing authorization holders and contract manufacturers alike -

    Poništi
  10. proslijedio/la je Tweet
    5. stu 2019.

    / - ➡️Accelerated drugs are more likely to be contract manufactured than regular products ➡️60% of orphan approvals were outsourced ➡️NMEs are far more likely to be outstood ➡️Small and midcap are increasingly turning to outsourcing

    Poništi
  11. 5. stu 2019.
    Poništi
  12. proslijedio/la je Tweet
    5. stu 2019.

    There is a huge capacity shortage for , says > Vetter and Piramal agree: “Capacity crunch,” says “Requires a mindset change,”

    Poništi
  13. proslijedio/la je Tweet
    31. lis 2019.

    If you are at next week, feel free to stop by my presentations. I will be sharing results of our latest research on and .

    Poništi
  14. proslijedio/la je Tweet
    Poništi
  15. proslijedio/la je Tweet
    Poništi
  16. proslijedio/la je Tweet
    Poništi
  17. proslijedio/la je Tweet

    "Because of the overall increase in approvals of innovator biologics, CMOs have in fact received more contracts for biologic dose ,” says editor in today's

    Poništi
  18. proslijedio/la je Tweet

    BREAKING: is set to be bought for $2.4bn by PE firm . Permira also acquired a majority stake in dose in July and owns CMO Lyophilization Services of New England

    Poništi
  19. proslijedio/la je Tweet

    Out now on the Intelligence Center: the Bio/Pharma Outsourcing Report: 💊 Which European country is leading API Containment 💊 Blockchain: a real answer to serialization ? 💊 Regulatory, API, Dose, Analytic news and more

    Poništi
  20. proslijedio/la je Tweet
    1. kol 2019.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·